Bharat Biotech's Covid-19 vaccine Covaxin (BBV152) is effective against Delta Plus (AY.1) variant of the coronavirus, according to a study by the Indian Council of Medical and Research
The domestically developed Covaxin is effective against the Delta plus variant of Covid-19, claims Indian Council of Medical Research (ICMR) in its study released on Monday.
Daily cases have grown persistently through July in Kerala and a few smaller north-eastern states
India has so far administered 461,518,479 vaccine doses. That is 1459.85 per cent of its total caseload, and 33.09 per cent of its population
India has so far administered 456,033,754 vaccine doses. That is 1444.4 per cent of its total caseload, and 32.7 per cent of its population
The Central government on Wednesday advised all States and UTs to conduct sero-prevalence surveys in consultation with the Indian Council of Medical Research (ICMR) to generate district-level data.
India averages 109 vaccinations per site and the UK 126. It has fully vaccinated only 6 per cent of its population, as against 53 per cent in the UK
India has so far administered 441,912,395 vaccine doses. That is 1405.53 per cent of its total caseload, and 31.69 per cent of its population
India has so far administered 435,196,001 vaccine doses. That is 1385.47 per cent of its total caseload, and 31.21 per cent of its population
India has so far administered 427,882,261 vaccine doses. That is 1365.63 per cent of its total caseload, and 30.68 per cent of its population
It may be premature to conclude that complications like lung fibrosis and increased thrombotic events due to COVID-19 are on the rise.
India has so far administered 423,417,030 vaccine doses. That is 1353.07 per cent of its total caseload, and 30.36 per cent of its population
India has so far administered 417,851,151 vaccine doses. That is 1336.79 per cent of its total caseload, and 29.96 per cent of its population
Govt should not get complacent about Covid management
Despite high seropositivity shown in data, the government has cautioned that around 400 million people in India were still vulnerable to the virus
Here are the top headlines of the day
Once India starts reopening schools, it will be wise to being with the primary section as children have a lower number of ace receptors to which virus attaches
A third of the population did not have SARS-CoV-2 antibodies, which means about 400 million people are still vulnerable to Covid infection, says ICMR official
ICMR has spent Rs 35 cr on Covaxin clinical trials